Regulated Information - Transparency Statement

Leuven, Belgium, 27 July 2018 – Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received transparency notifications on 27 July 2018 from Mr. Thomas M. Clay and his controlled entities (*Landon T. Clay 2017-1 Annuity Trust, Estate of Landon T. Clay, East Hill Hedge Fund LLC, Monadnock Charitable Lead Annuity Trust, Clay Fellowships Charitable Trust and The Clay Mathematics Institute, Inc.)* and from Mrs. Lavinia D. Clay.

On 23 July 2018 the Estate of Landon T. Clay, of which Thomas M. Clay is the executor of, transferred 1,570,656 shares to Lavinia D. Clay as required by the Will of the late Landon T. Clay.

Upon this transfer the voting percentage of Thomas M. Clay decreased to 4.68% and the voting percentage of Lavinia D. Clay increased from zero to 4.10%.

On 27 July 2018, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:

Shareholder	number of securities	% of voting rights
Baron Philippe Vlerick and entities controlled by him	2,324,719	6.07%
Novartis Pharma AG	2,177,226	5.69%
Mr Thomas M. Clay and entities controlled by him	1,790,899	4.68%
Mrs Lavinia D. Clay	1,570,656	4.10%

END

For further information please contact:

ThromboGenics	**Citigate Dewe Rogerson**
Wouter Piepers, Global Head of Corp Coms & Investor relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	David Dible/ Sylvie Berrebi/ Isabelle Andrews Tel: +44 20 7638 9571 thrombogenics@citigatedewerogerson.com

ThromboGenics®
Advancing Science. Enhancing Vision.™

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing novel treatments for back of the eye diseases with an innovative pipeline in diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics' clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME), which is in an ongoing Phase 2 clinical study in combination with Lucentis®, and THR-149, a plasma kallikrein inhibitor which is in a Phase 1 clinical study for DME. THR-687 (an integrin antagonist) is in late-stage preclinical development for the treatment of diabetic retinopathy and DME. THR-687 is expected to enter the clinic in H2 of 2018. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.

ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US).

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.

More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.